Market Overview

Biotie Therapies Surging Following IPO Debut

Share:
Related
Accorda Therapeutics Announces Final Results Of Tender Offer On Biotie Therapies
Acorda Files Tender Offer Document Relating to Public Tender Offer for Biotie Therapies with Finnish Financial Supervisory Authority

Shares of Biotie Therapies Corp. (NASDAQ: BITI) traded higher by more than 39 percent in their public debut.

The Finland-based firm is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. The company is developing a therapy to extend the efficacy of levodopa for Parkinson's disease.

Biotie also developed a product called Selincro to treat alcohol dependence. The therapy is commercialized by Lundbeck and remains a source of potential milestone payments and continuing royalties.

Shares began trading for the first time just before 11:00 AM on Thursday at $16.25 after originally pricing its offering of 3.76 million shares at $14.88/ADS. Shares of the company currently trade on the Finnish stock exchange under the ticket BTHV1.

Shares rose as high as $20.84 in Biotie's first day, but gave back some of the gains as volume tapered.

The company reported revenue of $871,000 in its first quarter (ending March 31) and recorded revenue of $5.10 million in 2014.

The company plans on using the proceeds from its IPO to fund its Phase 3 double-blind clinical trial on Tozadenant in Parkinson's through completion.

In addition, there are two other product candidates in its pipeline: SYN120 (for Parkinson's disease, dementia and Alzheimer's disease) and BTT1023 (treatment for primary sclerosing cholangitis). Both of these therapries are in early Phase 1 and 2 clinical trials.

Posted-In: IPO Levodopa neurodegenerative disease Tozadenant WingstopNews IPOs Movers

 

Related Articles (BITI)

View Comments and Join the Discussion!